论文部分内容阅读
血糖控制对2型糖尿病治疗管理至关重要,目前已有很多药物被批准用于糖尿病治疗,纳-葡萄糖共转运蛋白2抑制剂(SGLT-2i)正是在这种情况下应运而生~([1])。1 SGLT-2i作用机制及临床有效性在现已发现的6种纳-葡萄糖共转运蛋白(SGLT)中,SGLT2和SGLT1最为重要,其中SGLT2从肾小球滤过液重吸收90%的葡萄糖,SGLT1重吸收10%。SGLT2突变或功能缺失,可导致家族
Glycemic control is crucial for the management of type 2 diabetes, and many drugs have been approved for the treatment of diabetes. It is in this context that the Nano-glucose Cotransporter 2 Inhibitor (SGLT-2i) [1]). Mechanism and clinical efficacy of SGLT-2i SGLT2 and SGLT1 are the most important of the six kinds of nano-glucose co-transporters (SGLTs) that have been found. Among them, SGLT2 reabsorbs 90% of glucose from glomerular filtration fluid, SGLT1 reabsorbs 10%. SGLT2 mutation or loss of function, can lead to family